Background: The ESC regularly update the European guidelines on cardiovascular disease (CVD) prevention. By setting risk factor goals and target levels, as well as proposing the appropriate treatment options, physicians are guided in their patient treatment in clinical practice. Little is known about the cost-effectiveness of a comprehensive approach to tackle uncontrolled risk factor levels. This information could however be useful for policy makers to make transparent decisions. Purpose: The aim of this study was to assess the cost-effectiveness of maximal adherence to the guidelines in patients with a history of coronary heart disease (CHD). Maximal guideline adherence, is compared with the currently observed risk factor management based on individual patient data. Methods: An individual-based decision tree model was developed in order to model the cardiovascular risk in individual patients. The model uses the SMART risk score tool which estimates the 10-year risk for recurrent vascular events in patients with manifest cardiovascular disease. Analyses were based on the EUROASPIRE IV survey, which was initiated to assess whether the guidelines are being implemented in clinical practice. In the model, results from EUROASPIRE IV are considered as current care and compared with optimized adherence to the CVD guidelines. The latter was modelled, based on the published 2016 guidelines on CVD prevention. In addition to a base case scenario, scenario analyses were performed. Outcomes were expressed as an incremental cost-effectiveness ratio (ICER). Results: Data from 4,663 EUROASPIRE IV patients from 13 European countries were included in the analyses. The mean estimated 10 year risk for a recurrent vascular event amounts to 20.13%. Initiating maximal guideline adherence results in a mean ten year risk of 18.99%. In the base case scenario maximal adherence could result in an average QALY gain of 0.0321 and an additional cost of ?2290. An ICER of ?35,915/QALY was calculated when only considering high-risk patients (10 year CVD risk !20%) with decreasing ICERs in higher risk patients. Also, a dose response relationship was seen with lower ICERs in older patients and in those patients with higher risk reductions. A less conservative LDL target (<2.5mmol/ L vs. <1.8mmol/L) lowered the ICER to ?41,079/QALY and intensifying cholesterol treatment in high-risk patients (10 year CVD risk !20%) instead of high cholesterol patients lowered the ICER to ?34,900/QALY. Applying risk reduction to the CVD events instead of applying risk reductions to the risk factors lowered the ICER to ?37,763/QALY. Conclusion: Depending on the method used, better or worse ICERs were found. In addition, maximal guidelines adherence is more cost-effective in older patients, in higher risk patients, in patients with higher risk reductions and when using a less conservative LDL-C target. Current analyses advice to maximize guidelines adherence in particular patient subgroups. Since subsets of EVs in the LDL plasma fraction (LDL-EVs) relate with thrombin activity, we hypothesized that changes in LDL-EVs after statin therapy may differ from that of serum levels of coagulation proteins, providing insight into the effects of statins on coagulation. Methods The study was conducted in 666 subjects with available serum from the randomized placebocontrolled METEOR trial, a trial of the effect of rosuvastatin (40mg/day) on two-year progression of common carotid intima-media thickness in patients with subclinical atherosclerosis (nplacebo=189, nrosuvastatin=477). Levels of the coagulation proteins von Willebrand Factor (VWF), SerpinC1 and plasminogen were measured in serum and in the LDL co-precipitated EVs (LDL-EVs). Changes from baseline to end of study in protein levels in LDL-EVs and in serum were compared between the rosuvastatin group and the placebo group. Results LDL-EV levels of plasminogen and VWF increased with rosuvastatin treatment compared to placebo (mean change of 126AE8 versus 17AE12 mg/mL for plasminogen (p<0.001) and 310AE60 versus 64AE55 mg/mL for VWF (p=0.015)). There was no difference between groups for change in LDL-EV-SerpinC1 (Table 1 ). The increase of LDL-EV-plasminogen was closely related to the reduction in LDL: the more LDL lowering, the larger the increase in LDL-EVplasminogen levels (beta=1.24, 95%CI=0.84-1.64, p<0.001). In contrast, serum levels of plasminogen increased to a lesser extent with rosuvastatin compared to placebo (23AE29 versus 67AE17 mg/mL, p=0.024) and serum levels of VWF showed no significant difference between both groups. Conclusion Rosuvastatin increases LDL-EV coagulation proteins plasminogen and VWF in patients with subclinical atherosclerosis, an effect which is different from the effect of rosuvastatin on the same proteins in serum. This identifies LDL-EVs as a new possible intermediate between statin therapy and coagulation NHIS-NSC 2002-2013 which is a sample of about one million representative of Korean population, 139,659 subjects were selected who were over 20 years of age as of year 2002, with available data of routine health check and free of diagnosis of ischemic heart disease, stroke, heart failure or cancer during 2002 and 2003. Cause of death was identified by the International Classification of Diseases (ICD) code in death certificate and deaths by ICD codes beginning with 'I' were classified as cardiovascular mortality. Socioeconomic status was stratified by income as low (lower 30 percentile), high (higher 30 percentile) and middle, which was reclassified annually. Shift in SES was defined as any change in the income class from baseline during the follow-up period.
Funding Acknowledgements: Supported by Center Grant, CS-IRG grant, ATTRaCT grant, NUS Start-up grant in Singapore; Queen of Hearts, KNAW grant in Netherlands and AstraZeneca Topic: Basic Science -Other Background and Purpose Low-density lipoprotein (LDL) levels and coagulation proteins are associated with the risk of cardiovascular disease. Statins may have pleiotropic including anticoagulant effects in addition to LDL reduction. Plasma extracellular vesicles (EVs) are small bilayer membrane vesicles involved in various biological processes including coagulation. Since subsets of EVs in the LDL plasma fraction (LDL-EVs) relate with thrombin activity, we hypothesized that changes in LDL-EVs after statin therapy may differ from that of serum levels of coagulation proteins, providing insight into the effects of statins on coagulation. Methods The study was conducted in 666 subjects with available serum from the randomized placebocontrolled METEOR trial, a trial of the effect of rosuvastatin (40mg/day) on two-year progression of common carotid intima-media thickness in patients with subclinical atherosclerosis (nplacebo=189, nrosuvastatin=477). Levels of the coagulation proteins von Willebrand Factor (VWF), SerpinC1 and plasminogen were measured in serum and in the LDL co-precipitated EVs (LDL-EVs). Changes from baseline to end of study in protein levels in LDL-EVs and in serum were compared between the rosuvastatin group and the placebo group. Results LDL-EV levels of plasminogen and VWF increased with rosuvastatin treatment compared to placebo (mean change of 126AE8 versus 17AE12 mg/mL for plasminogen (p<0.001) and 310AE60 versus 64AE55 mg/mL for VWF (p=0.015)). There was no difference between groups for change in LDL-EV-SerpinC1 (Table 1) . The increase of LDL-EV-plasminogen was closely related to the reduction in LDL: the more LDL lowering, the larger the increase in LDL-EVplasminogen levels (beta=1.24, 95%CI=0.84-1.64, p<0.001). In contrast, serum levels of plasminogen increased to a lesser extent with rosuvastatin compared to placebo (23AE29 versus 67AE17 mg/mL, p=0.024) and serum levels of VWF showed no significant difference between both groups. Conclusion Rosuvastatin increases LDL-EV coagulation proteins plasminogen and VWF in patients with subclinical atherosclerosis, an effect which is different from the effect of rosuvastatin on the same proteins in serum. This identifies LDL-EVs as a new possible intermediate between statin therapy and coagulation Background.Many key risk factors such as smoking, hypertension, high cholesterol, obesity for major chronic disease including cardiovascular diseases are modifiable. The WHO Global Action Plan for prevention and control of noncommunicable diseases outlines the need to monitor the population levels of these risk factors and changes on them. For many of these indicators, sample based health examination surveys (HES) are most reliable and often only data source. However, the usability of data from a HES is dependent on the representativeness of collected data for the target population. Low participation rate may decrease the representativeness. Purpose: To investigate potential non-response bias in key risk factors for major chronic diseases obtained from a series on national HESs in Finland. Methods: Data from the National FINRISK Study, which is a series of cross-sectional population based HESs among adults (25-74 years), conducted every 5 years in 1972-2012 were used. In total 98,050 persons were invited to these surveys over the years. These persons were randomly selected from the population register. Both participants and non-participants were linked to the national causes of death register. The samples were followed up for death until the end of 2014, the average follow-up time being 19.3 years and a maximum of 43 years. The follow-up included a total of 1,896,729 person years. Results: During one year follow-up, non-participating men had 2.7 (95% CI: 2.0,3.8) times higher cardiovascular disease (CVD) mortality than participants. The excess mortality decreased with increasing follow-up time, but still in 43 years' follow-up, non-participants had 1.9 (1.7,2.0) times higher total mortality. Among women, 4.9 (2.5,9.5) times excess CVD mortality of non-participants was observed during one year follow-up and 2.1 (1.9,2.3) times higher in 43 years' follow-up. Excess mortality of non-participants was particularly high for causes related to smoking, alcohol, mental health, CHD, injuries and suicides, in both men and women. Conclusion(s). The results indicate that survey participants and non-participants differ from each other by health (mental health and CHD) and health behaviours (smoking and heavy alcohol use). High hazard rates for one year follow-up indicate that non-participants include more severely ill persons than participants. Regardless of the length of the follow-up time, excess mortality of non-participants was observed. This emphasizes the importance of efforts to achieving high participation rates in surveys and use of statistical methods for adjusting for non-participation when population level prevalences of risk factors are estimated using HES data.
PERindopril GENEtic Association Study (PERGENE) Funding Acknowledgements: The PERGENE study is funded by grants from: Dutch Heart Foundation and Netherlands Organization for Health Research and Development (ZonMW). Topic: Pharmacology and Pharmacotherapy -Other Background: Vascular endothelial growth factor (VEGF) and its kinase insert domain-containing receptor (KDR) have been shown to exert both deleterious and beneficial effects on the vascular wall. Variation in the VEGF and KDR genes affect gene expression or the function of the encoded protein. Studies that have investigated the relationship between VEGF/KDR polymorphisms and cardiovascular outcome are relatively small, studied only a limited number of variants and have yielded inconsistent results. Also, there are currently no studies that have investigated whether the ACE-inhibitor treatment benefit on cardiovascular outcome is modified by these polymorphisms. Purpose: We investigated the relationship between seven VEGF/KDR variants with cardiovascular outcome, as well as with the magnitude of the treatment benefit provided by ACEinhibitors. Methods: In PERGENE, a substudy of the EUROPA trial, patients with stable coronary artery disease (CAD) were randomized to the ACE-inhibitor perindopril (8mg daily) or placebo during a median follow-up of 4.3 years. Four VEGF (-2578C/A, -1154G/A, +405G/C, +936C/T) and three KDR (-604T/C, +1192G/A, +1719A/T) polymorphisms were determined in 7976 patients. The endpoint was a composite of cardiovascular mortality, myocardial infarction, and cardiac arrest. Results: Although no associations were present between any of the individual VEGF/KDR polymorphisms or their haplotypes with cardiovascular events in multivariable analysis, statistical interactions between ACE-inhibitor therapy and multiple genotypes were present. Minor allele (A) carriers of -2578C/A and +1192G/A, as well as common allele (G) carriers of +405G/C benefited most from ACE-inhibitors on outcome, as compared to their homozygous common allele genotype. Conclusions: There was no association between VEGF/KDR polymorphisms and cardiovascular outcome. However, multiple VEGF/KDR polymorphisms modified the treatment benefit provided by ACE-inhibitors on cardiovascular outcome. While VEGF/KDR polymorphisms cannot be used for risk stratification in patients with stable CAD, they Abstract No: 45. might rather be used for selection of patients that have an incremental treatment benefit of ACE-inhibitors with regard to prevention of adverse cardiovascular outcome. Funding Acknowledgements: Topic: Secondary Prevention Aim: to research the presence of genetic polymorphisms rs7412+rs429358 APOE, rs670 APNA1,rs662799 APNA5 with severe myocardial infarction, and also with the development of in-hospital and long-term complications, to detail the genetic polymorphism of the above with the greatest predictive ability. Materials and Methods: 358 patients with ST-segment elevation myocardial infarction (STEMI) were admitted to the Cardiology Dispensary. All blood samples for genotyping were obtained on days 2-14th. DNA was isolated from peripheral blood leukocytes using phenol-chloroform extraction followed by ethanol precipitation. During hospitalization evaluated laboratory and instrumental parameters. The endpoints at the time of hospitalization were death, recurrent STEMI, acute ischemic stroke, the development of early post-infarction angina. At 1 year after STEMI assessment endpoints was the same. Statistical analysis was performed using SPSS Statistics 17.0. Results: revealed that patients with the development of in-hospital recurrent of STEMI the G allele of the gene APNA1 met significantly more often (OR=3,17; 95% CI=1,44-7.29; p=0.004). In the analysis of indicators of lipid revealed that carriers of the GG genotype of the gene APNA1 level of TG was significantly higher and amounted to 2.32 [0,41; 6,00] mmol/l compared to carriers of genotype AA, where the TG level was 1.84 [0,92; 2,95] mmol/l, p=0.02. Patients who died in the year since STEMI rarely met G allele of the gene rs670 APNA1 (OR=0,35; 95% CI=0,14-0,84; p=0.02). Revealed that patients with critical decrease of LVEF below 40% on admission to the hospital, five-fold more common had genotype e4/e4 rs429358+rs7412 gene APOE as against the genotypes e2/e2 and e2/e3 (OR=5,25; 95% CI=1,06-27.39; p=0.04). In addition, this genotype was a marker of more severe atherosclerosis. So, stenosis of extracranial arteries more than 30%, were detected with allele e4 almost 2.5 times more often than the allele e2 (OR=2,44; 95% CI=1,17-5,12; p=0.02). Severe coronary artery disease 23 points and above on a scale SYNTAX also was significantly more prevalent in carriers allele e4 against carriers of other alleles (OR=2,10; 95% CI=1,26-3,51; p=0.005). In patients with the development in the year following their clinic progressive angina significantly more prevalent e4 allele of polymorphism rs429358+rs7412 gene the APOE (OR=1,88; 95% CI=1,00-3,48; p=0.047). For other endpoints no differences is found. It was revealed that the carriers of the genotype QQ rs662799 APNA5 the concentration of blood TG was significantly higher than in carriers of genotype TT (p=0.008). HDL levels blood the carriers of CC genotype was lower than carriers of genotype TT (p=0,0005). Conclusion: were found relationships of the genes of apolipoproteins with severe STEMI and adverse in-hospital prognosis. Background: Type-2 diabetes (T2D) increases the risk of having cardiovascular disease (CAD) more markedly in women than in men, but sex-differences in coronary plaque composition in these patients is still poorly elucidated, especially in the early stages of T2D. Coronary plaque composition is an independent determinant for the evolution of coronary plaques and clinical outcomes. An association between biochemical markers of inflammation and coronary plaque composition may be of importance regarding identification of high-risk patients with T2D already at an early stage. Purpose: The purposes of this study were to determine gender differences in coronary plaque composition and inflammatory biomarkers in patients with newly diagnosed T2D without known cardiovascular disease. Methods: A total of 88 patients with newly diagnosed (<1 year) T2D underwent contrastenhanced CTA. Advanced plaque analysis including total plaque volume and volumes of plaque components (calcified plaque [CP] , non-calcified plaque [NCP] , including low-attenuation [LD-NCP] was performed using validated semi-automated software. Plasma concentrations of inflammatory biomarkers were determined. Results: There were no significant differences between men (n=60) and women (n=28 In the female population extent of CP (coefficient 3.798, p<0.05) and LD-NCP (coefficient 4.679, p<0.05) volumes increased with hypercholesterolemia. In the male population only age was associated with the presence of plaque, (CP; oddsratio 1.19, p<0.05 and LD-NCP; oddsratio 1.20, p<0.05). Conclusions: In newly diagnosed T2D, coronary plaque composition differed between genders. The non-calcified plaque component was highest in women, while the opposite was found for absolute coronary plaque volumes, plaque burden and coronary calcification. Moreover, women had significantly higher concentrations of inflammatory biomarkers. This study indicates different associations between inflammatory biomarkers and coronary plaque components in men and women with a new diagnosis of T2D.
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